BRPI0900961B8 - métodos e kit para diagnóstico de leishmaniose - Google Patents

métodos e kit para diagnóstico de leishmaniose

Info

Publication number
BRPI0900961B8
BRPI0900961B8 BRPI0900961A BRPI0900961A BRPI0900961B8 BR PI0900961 B8 BRPI0900961 B8 BR PI0900961B8 BR PI0900961 A BRPI0900961 A BR PI0900961A BR PI0900961 A BRPI0900961 A BR PI0900961A BR PI0900961 B8 BRPI0900961 B8 BR PI0900961B8
Authority
BR
Brazil
Prior art keywords
genes
leishmaniasis
antigens
dogs
encode
Prior art date
Application number
BRPI0900961A
Other languages
English (en)
Inventor
Mendes Pereira Andrea
Carlos Gomes Antonio
Garboggini Melo De Pinheiro Cristiane
Domingos Da Silva Edimilson
Barbalho Magalhães Franklin
Gileno De Sá Oliveira Geraldo
Carlos Pontes De Carvalho Lain
Ramires Dos Santos Lenita
Antonio Araujo Silvany Marco
Cristina Aquino Teixeira Márcia
De Freitas Pinheiro Nathanael Jr
Pompílio De Melo Neto Osvaldo
Oliveira Meira Santos Patricia
Evangelista Fraga Ricardo
Luis Conrado Dos Santos Washington
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to BRPI0900961A priority Critical patent/BRPI0900961B8/pt
Priority to PCT/BR2010/000083 priority patent/WO2010108245A2/pt
Publication of BRPI0900961A2 publication Critical patent/BRPI0900961A2/pt
Publication of BRPI0900961B1 publication Critical patent/BRPI0900961B1/pt
Publication of BRPI0900961B8 publication Critical patent/BRPI0900961B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

uso de antígenos de leishmania em método diagnóstico, vacina e terapia para leishmaniose. a presente invençào se refere ao uso de antígenos recombinantes diferentes entre si obtidos a partir de genes de leishmania chagasi/leishrnania infantum, em ensaios visando identificar, detectar e quantificar anticorpos específicos em material biológico, incluindo soro, plasma, saliva e urina, obtido de seres humanos, de càes e de outros hospedeiros vertebrados da lei shraania. estes antígenos recombinantes ou seus genes ou parte dos genes que os codificam podem ser utilizados para o diagnóstico das leishmanioses, quer seja a infecção e/ou a doença. a presente invenção se refere ainda ao uso desses antígenos recombinantes, ou genes ou parte dos genes que os codificam ou ainda formulações contendo esses antígenos, para o tratamento e/ou vacinas para seres humanos, cães e outros hospedeiros vertebrados, contra leishmanioses.
BRPI0900961A 2009-03-23 2009-03-23 métodos e kit para diagnóstico de leishmaniose BRPI0900961B8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0900961A BRPI0900961B8 (pt) 2009-03-23 2009-03-23 métodos e kit para diagnóstico de leishmaniose
PCT/BR2010/000083 WO2010108245A2 (pt) 2009-03-23 2010-03-22 Uso de antígenos de leishmania em método diagnóstico, vacina e terapia para leishmaniose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0900961A BRPI0900961B8 (pt) 2009-03-23 2009-03-23 métodos e kit para diagnóstico de leishmaniose

Publications (3)

Publication Number Publication Date
BRPI0900961A2 BRPI0900961A2 (pt) 2010-12-21
BRPI0900961B1 BRPI0900961B1 (pt) 2020-10-06
BRPI0900961B8 true BRPI0900961B8 (pt) 2021-07-13

Family

ID=42781588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0900961A BRPI0900961B8 (pt) 2009-03-23 2009-03-23 métodos e kit para diagnóstico de leishmaniose

Country Status (2)

Country Link
BR (1) BRPI0900961B8 (pt)
WO (1) WO2010108245A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015024877A2 (pt) * 2013-03-28 2017-10-10 Infectious Disease Res Inst vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
WO2016055836A1 (pt) * 2014-10-09 2016-04-14 Universidade Federal De Minas Gerais - Ufmg Processo de produção e uso da proteína rk39-kddr e kit para diagnóstico de leishmaniose
BR102019003639A2 (pt) * 2019-02-22 2021-11-16 Fundação Oswaldo Cruz Proteína quimérica, seu método para produção e uso, bem como molécula de ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição para diagnóstico de leishmaniose, kit de diagnóstico de leishmaniose e método de diagnóstico de leishmaniose in vitro

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
CA2540736A1 (en) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
US20090028932A1 (en) * 2005-04-15 2009-01-29 Wilson Mary E Vaccine formulations for leishmania
WO2007121184A2 (en) * 2006-04-10 2007-10-25 The Infectious Disease Research Institute Inc. Compounds and methods for diagnosis and treatment of leishmaniasis

Also Published As

Publication number Publication date
WO2010108245A3 (pt) 2011-05-12
BRPI0900961A2 (pt) 2010-12-21
WO2010108245A2 (pt) 2010-09-30
BRPI0900961B1 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
Gordon et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant
IN2015DN03125A (pt)
Goodell et al. Probability of detecting influenza A virus subtypes H1N1 and H3N2 in individual pig nasal swabs and pen-based oral fluid specimens over time
EP2293078A3 (en) Method for diagnosis of a bacterial infection
EP2361930A3 (en) Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
Horzinek Vaccine use and disease prevalence in dogs and cats
Xiong et al. Protective efficacy of a live attenuated Mycoplasma hyopneumoniae vaccine with an ISCOM-matrix adjuvant in pigs
BRPI0900961B8 (pt) métodos e kit para diagnóstico de leishmaniose
Switaj et al. Cowpox after a cat scratch-case report from Poland
WO2007005627A8 (en) Tuberculosis antigen detection assays and vaccines
Yi et al. Detecting Newcastle disease virus in combination of RT-PCR with red blood cell absorption
BRPI0412194A (pt) composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida
MX2013004069A (es) Antigenos inmunoreactivos de mycoplasma haemofelis e inmunoensayos de diagnostico.
BR0213656A (pt) composição, método para a obtenção de uma resposta imune à tênia, método para vacinar um mamìfero contra tênia, vacina, método para pemitir a vacinação, métodos para a redução de perda sangüìnea, para a redução do tamanho da tênia e para a redução de aflição por tênia em um paciente infectado com tênia, antìgeno recombinante sintético e antìgeno
Launay et al. Factors associated with humoral immune response to pandemic A/H1N1 (v) 2009 influenza vaccine in cystic fibrosis
Terregino et al. Conventional H5N9 vaccine suppresses shedding in specific-pathogen-free birds challenged with HPAI H5N1 A/chicken/Yamaguchi/7/2004
EP2527358A3 (en) Diagnostic assay
Montakhab-Yeganeh et al. Immunogenic properties of empty pcDNA3 plasmid against zoonotic cutaneous leishmaniasis in mice
US11034735B2 (en) Hybrid peptide, set of hybrid peptides, composition, uses of the hybrid peptide, method for inducing an immune response and kits
IN2012DN02304A (pt)
WO2009108738A3 (en) Methods for inducing the differentiation of blood monocytes into functional dendritic cells
WO2007118292A8 (en) MEMBRANE PROTEIN Sm29 OF SCHISTOSOMA MANSONI AND USES THEREOF FOR TREATING AND DIAGNOSING SCHISTOSOMIASIS
BRPI0412419A (pt) proteìna de babésia, ácido nucleico, fragmento de cdna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, vacina, método para a preparação de uma vacina, uso de uma proteìna ou um fragmento imunogênico de referida proteìna, e, testes diagnósticos para a detecção de um ácido nucleico associado com, para a detecção de anticorpos contra, e para a detecção de material antigênico de um organismo da famìlia babesiidae
Sagols et al. Evaluation of the humoral immune response after the first annual CaniLeish booster vaccination
BR112015004085A2 (pt) método para cultivar uma cepa de rotavírus (rv); método para gerar uma rv3 atenuada em células vero; rv3 adaptada à vero isolada; composição de rv morto ou vivo atenuado; método para vacinar um indivíduo humano contra infecção por rv; método para tratar um indivíduo humano com uma infecção por rv ou em risco de desenvolver uma infecção ou reinfecção por rv; uso da rv3 de vero; anticorpo isolado; e método para detectar ou monitorar a rv3 de vero

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2596 DE 06/10/2020 QUANTO AO INVENTOR.

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2767 DE 16-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.